» Articles » PMID: 16603398

Activation of IKK by TNFalpha Requires Site-specific Ubiquitination of RIP1 and Polyubiquitin Binding by NEMO

Overview
Journal Mol Cell
Publisher Cell Press
Specialty Cell Biology
Date 2006 Apr 11
PMID 16603398
Citations 509
Authors
Affiliations
Soon will be listed here.
Abstract

The receptor interacting protein kinase 1 (RIP1) is essential for the activation of nuclear factor kappaB (NF-kappaB) by tumor necrosis factor alpha (TNFalpha). Here, we present evidence that TNFalpha induces the polyubiquitination of RIP1 at Lys-377 and that this polyubiquitination is required for the activation of IkappaB kinase (IKK) and NF-kappaB. A point mutation of RIP1 at Lys-377 (K377R) abolishes its polyubiquitination as well as its ability to restore IKK activation in a RIP1-deficient cell line. The K377R mutation of RIP1 also prevents the recruitment of TAK1 and IKK complexes to TNF receptor. Interestingly, polyubiquitinated RIP1 recruits IKK through the binding between the polyubiquitin chains and NEMO, a regulatory subunit of the IKK complex. Mutations of NEMO that disrupt its polyubiquitin binding also abolish IKK activation. These results reveal the biochemical mechanism underlying the essential signaling function of NEMO and provide direct evidence that signal-induced site-specific ubiquitination of RIP1 is required for IKK activation.

Citing Articles

NEMO Family of Proteins as Polyubiquitin Receptors: Illustrating Non-Degradative Polyubiquitination's Roles in Health and Disease.

Wu C Cells. 2025; 14(4).

PMID: 39996775 PMC: 11854354. DOI: 10.3390/cells14040304.


Mutations disrupting the kinase domain of IKKα lead to immunodeficiency and immune dysregulation in humans.

Riller Q, Sorin B, Courteille C, Ho-Nhat D, Le Voyer T, Debray J J Exp Med. 2025; 222(2.

PMID: 39812688 PMC: 11734625. DOI: 10.1084/jem.20240843.


Deubiquitinases as novel therapeutic targets for diseases.

Xian Y, Ye J, Tang Y, Zhang N, Peng C, Huang W MedComm (2020). 2024; 5(12):e70036.

PMID: 39678489 PMC: 11645450. DOI: 10.1002/mco2.70036.


Inhibition of cathepsin L ameliorates inflammation through the A20/NF-κB pathway in endotoxin-induced acute lung injury.

Yang S, Chen K, Yu J, Jin Z, Li Z, Yu Y iScience. 2024; 27(11):111024.

PMID: 39559762 PMC: 11570319. DOI: 10.1016/j.isci.2024.111024.


Caspase-8 in inflammatory diseases: a potential therapeutic target.

Zhang W, Zhu C, Liao Y, Zhou M, Xu W, Zou Z Cell Mol Biol Lett. 2024; 29(1):130.

PMID: 39379817 PMC: 11463096. DOI: 10.1186/s11658-024-00646-x.